Thymosin Alpha-1

Thymosin Alpha-1 is a 28-amino-acid peptide used as an immune modulator, with community use cases focused on immune support and antiviral support. Typical protocols involve doses of 500 mcg/day, with daily administration being most common, although schedules vary. The off-label evidence base for this peptide is thinner than often suggested, with many exploratory indications lacking posted results, which is a key tradeoff to consider when using Thymosin Alpha-1.

Half-life~2 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.52.83.93.43.24.0

Research Evidence

Evidence shape

Thymosin Alpha-1 carries a moderate evidence tier, supported by limited human literature and a broad range of exploratory clinical research. While 53 trials have been registered across 49 distinct indications—including oncology, infectious disease, and inflammatory conditions—the vast majority remain thin, single-trial investigations with only one study currently reporting results. This high volume of early-stage, fragmented research indicates that while the peptide has been widely tested across diverse clinical settings, it lacks the robust, multi-trial validation required to establish consistent therapeutic outcomes.

Depthhow much
53 registered trials
21 completed · 1 with posted results · 14 recruiting / active · combined n=189
Breadthhow many areas
49 indications mapped
1 with results · 44 thin / exploratory · 1 animal-only · 42 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
12 distinct sponsors · AE table from NCT04428008 · 25 linked publications on registered trials
Breadth and depth78 rows captured
Human
direct clinical signal
54
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Thymosin Alpha-1 side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Lilipeptide
China
500 mg×10
$110.00
$0.22/mg
2
Bio Hack London
GB
100 mg
$79.19
$0.792/mg
3
Northwest Peptides
--
10 mg
$7.99
$0.8/mg
4
Swiss Chems
International
500 mg×10
$639.90
$1.28/mg
5
Nurev Peptides
--
10 mg
$13.99
$1.4/mg
6
Mrbeetoe
--
50 mg
$90.00
$1.8/mg

price offers can be sorted by column

1-6 of 209

Thymosin Alpha-1 dosing & protocol

How Thymosin Alpha-1 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 20
Typical dose
1.6 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 8 reported doses · darker = more
Frequency
weekly
Route
subQ

Trials administered 1.6 mg subcutaneously, with regimens reported as either daily or weekly; some studies used a weight‑based dose of 1000 mg/m² twice daily.

20 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 29
Typical dose
500 µg100 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 31 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mixed
Route
subQ

No single cadence dominates across 29 community reports: daily users cluster around 500 mcg, those dosing two to three times per week around 1.5–1.6 mg, and weekly reporters also around 1.6 mg — with more than a third giving no schedule at all.

29 sources

Related peptides

ThymalinLL-37ThymulinVIP